摘要
[目的]观察糖尿病肾病(DN)患者川芎嗪治疗前后血清中转化生长因子-β1(TGF-β1)的变化,探讨川芎嗪对DN疗效及可能机制。[方法]42例糖尿病肾病患者,治疗前及川芎嗪治疗21d后留取空腹静脉血液及24h尿标本,ELISA法检测血清TGF-β1,放免法测定24h尿蛋白排泄率。[结果]:糖尿病肾病患者治疗后血清TGF-β1较治疗前明显下降(P<0.05),尿微量白蛋白排泄率降低(P<0.05)。[结论]川芎嗪对早期糖尿病肾病具有良好治疗效果,抑制TGF-β1的表达可能是其肾脏保护作用的机制之一。
[Objective] To observe DN patients＇ changes on serum TGF-β1 after treated with Ligustrazine, and explore the curative effect and mechanism. [Method] For 42 cases of DN patients, take fasting vein blood and 24h urine sample, test serum TGF-β1 with ELLISA method, measure 24h urinary protein emiction rate with radioimmuno method before treatment and after 21 weeks of treating with Ligustrazine. [Result] After treatment, TGF-β1 was much reduced than before treatment（P〈0.05）, the urinary slight albumin emiction rate was decreased too（P〈0.05）. [Conclusion] Ligustrazine has good curative effect on DN, inhibiting TGF-β1 expression may be one of the mechanisms of its protecting kidney.
出处
《浙江中医药大学学报》
CAS
2007年第4期435-436,共2页
Journal of Zhejiang Chinese Medical University
